Chorea as a first manifestation in young patients with systemic lupus erythematosus who was initially diagnosed with rheumatic Fever.

Albishri JA.

Clin Med Insights Case Rep. 2012;5:19-21. doi: 10.4137/CCRep.S9143.

Downregulation of genes involved in metabolism and oxidative stress in the peripheral leukocytes of Huntington's disease patients.

Chang KH, Chen YC, Wu YR, Lee WF, Chen CM.

PLoS One. 2012;7(9):e46492. doi: 10.1371/journal.pone.0046492.

Aspiration pneumonia and death in Huntington's disease.

Heemskerk AW, Roos RA.

Version 2. PLoS Curr. 2012 Jan 30 [revised 2012 Jan 1];4:RRN1293.

NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease.

Pouladi MA, Brillaud E, Xie Y, Conforti P, Graham RK, Ehrnhoefer DE, Franciosi S, Zhang W, Poucheret P, Compte E, Maurel JC, Zuccato C, Cattaneo E, Néri C, Hayden MR.

Neurobiol Dis. 2012 Dec;48(3):282-9. doi: 10.1016/j.nbd.2012.06.026.

Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease.

Chiodi V, Uchigashima M, Beggiato S, Ferrante A, Armida M, Martire A, Potenza RL, Ferraro L, Tanganelli S, Watanabe M, Domenici MR, Popoli P.

Neurobiol Dis. 2012 Mar;45(3):983-91. doi: 10.1016/j.nbd.2011.12.017.

Targeting neuro-inflammatory cytokines and oxidative stress by minocycline attenuates quinolinic-acid-induced Huntington's disease-like symptoms in rats.

Kalonia H, Mishra J, Kumar A.

Neurotox Res. 2012 Nov;22(4):310-20.

Does Huntington's disease enhance cephalad spread during neuraxial anesthesia for cesarean section?

Draisci G, Sbaraglia F, Pinto R, Zanfini BA, Frassanito L, Catarci S.

J Clin Anesth. 2012 Sep;24(6):516-7. doi: 10.1016/j.jclinane.2011.09.011. No abstract available.

An event-based model for disease progression and its application in familial Alzheimer's disease and Huntington's disease.

Fonteijn HM, Modat M, Clarkson MJ, Barnes J, Lehmann M, Hobbs NZ, Scahill RI, Tabrizi SJ, Ourselin S, Fox NC, Alexander DC.

Neuroimage. 2012 Apr 15;60(3):1880-9. doi: 10.1016/j.neuroimage.2012.01.062.

Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease.

Chen JJ, Salat DH, Rosas HD.

Neuroimage. 2012 Jan 16;59(2):1043-51. doi: 10.1016/j.neuroimage.2011.08.112.

TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease.

Lee JH, Lee JM, Ramos EM, Gillis T, Mysore JS, Kishikawa S, Hadzi T, Hendricks AE, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Gellera C, Gomez-Tortosa E, Ayuso C, Suchowersky

Biochem Biophys Res Commun. 2012 Aug 3;424(3):404-8.

An evidence-based approach in the treatment of Huntington's disease.

Mestre TA, Ferreira JJ.

Parkinsonism Relat Disord. 2012 May;18(4):316-20. doi: 10.1016/j.parkreldis.2011.10.021. Review.

Loss of junctophilin-3 contributes to Huntington disease-like 2 pathogenesis.

Seixas AI, Holmes SE, Takeshima H, Pavlovich A, Sachs N, Pruitt JL, Silveira I, Ross CA, Margolis RL, Rudnicki DD.

Ann Neurol. 2012 Feb;71(2):245-57. doi: 10.1002/ana.22598.

Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease.

Prime ME, Brookfield FA, Courtney SM, Gaines S, Marston RW, Ichihara O, Li M, Vaidya D, Williams H, Pedret-Dunn A, Reed L, Schaertl S, Toledo-Sherman L, Beconi M, Macdonald D, Muñoz-Sanjuan I, Domingu

ACS Med Chem Lett. 2012 Aug 9;3(9):731-5. doi: 10.1021/ml3001352.

Paraventricular nucleus neuropeptide expression in Huntington's disease patients.

van Wamelen DJ, Aziz NA, Anink JJ, Roos RA, Swaab DF.

Brain Pathol. 2012 Sep;22(5):654-61. doi: 10.1111/j.1750-3639.2012.00565.x.

CCG polymorphisms in the huntingtin gene have no effect on the pathogenesis of patients with Huntington's disease in mainland Chinese families.

Zhang BR, Tian J, Yan YP, Yin XZ, Zhao GH, Wu ZY, Gu WH, Xia K, Tang BS.

J Neurol Sci. 2012 Jan 15;312(1-2):92-6. doi: 10.1016/j.jns.2011.08.015.